Free Trial

Ceapro Q2 2023 Earnings Report

Ceapro logo
$0.17 0.00 (0.00%)
(As of 06/6/2024)

Ceapro EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ceapro Revenue Results

Actual Revenue
$1.39 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ceapro Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

How to piss off your liberal friends… and profit from it (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now

Ceapro Earnings Headlines

Rare "crisis signal" triggers for third time in U.S. market
A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.
See More Ceapro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ceapro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ceapro and other key companies, straight to your email.

About Ceapro

Ceapro (OTCMKTS:CRPOF), a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

View Ceapro Profile

More Earnings Resources from MarketBeat

Upcoming Earnings